Glancy Binkow & Goldberg LLP Announces Investigation on Behalf of Shareholders of Aegerion Pharmaceuticals, Inc.

LOS ANGELES--()--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of shareholders of Aegerion Pharmaceuticals, Inc. (“Aegerion” or the “Company”) (NASDAQ:AEGR) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by Aegerion concerning the Company’s operations and financial performance and prospects.

PLEASE CONTACT US AT (212) 682-5340, TOLL-FREE AT (888) 773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM,TO DISCUSS THIS MATTER OR OTHER POTENTIAL CLAIMS IF YOU ARE A LONG-TERM SHAREHOLDER OF AEGERION. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.

Aegerion markets its cholesterol drug Juxtapid in the United States. Juxtapid is the sole FDA-approved Aegerion product. Juxtapid was approved by U.S. health regulators in December 2012 to treat patients with homozygous familial hypercholesterolemia (HoFH), a rare genetic disease that impairs the function of the receptor responsible for removing LDL-C or “bad” cholesterol from the blood.

The investigation is related to the Company’s January 9, 2014, announcement that the Company received a subpoena from the U.S. Department of Justice requesting documents on its marketing and sale of Juxtapid. Reportedly, Chief Executive Officer Marc Beer received a warning letter from the Food and Drug Administration in November about comments in an interview on CNBC. According to sources, the FDA said Beer’s statements “provide evidence that Juxtapid is intended for new uses, for which it lacks approval and for which its labeling does not provide adequate directions for use.” The Company reportedly is also reducing its previously announced projections for FY 2014. Aegerion dropped as much as 16 percent to $61.00 in response during extended trading.

If you purchased Aegerion common stock between April 30, 2013 and January 9, 2014, if you have information or would like to learn more about these claims, or if you are a long-term shareholder of Aegerion and have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg
(888) 773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh
(212) 682-5340
shareholders@glancylaw.com
www.glancylaw.com

Release Summary

Contact Glancy Binkow & Goldberg LLP if you purchased Aegerion Pharmaceuticals, Inc. common stock between April 30, 2013 and January 9, 2014.

Sharing

Contacts

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg
(888) 773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh
(212) 682-5340
shareholders@glancylaw.com
www.glancylaw.com